Kenya Neurology Clinical Trials Market Report 2022 to 2030

Kenya Neurology Clinical Trials Market Analysis

$ 3999

The Kenya Neurology Clinical Trials market is projected to grow from $3.66 Mn in 2022 to $6.1 Mn by 2030, registering a CAGR of 6.6% during the forecast period of 2022 - 2030. The market will be driven by investments in healthcare infrastructure by the Kenyan government and a favourable regulatory environment. The market is segmented by phase, by study design & by indication. Some of the major players include Merck & Co., Inc., Novartis International AG, and Roche Holding AG.

ID: IN10KECT005 CATEGORY: Clinical Trials GEOGRAPHY: Kenya AUTHOR: Vidhi Upadhyay

Buy Now

Kenya Neurology Clinical Trials Market Executive Summary

The Kenya Neurology Clinical Trials market is projected to grow from $3.66 Mn in 2022 to $6.1 Mn by 2030, registering a CAGR of 6.6% during the forecast period of 2022 - 2030. According to the International Finance Corporation (IFC), Sub-Saharan Africa has 11% of the world's population but bears 24% of the global illness burden in terms of human and financial expenses. Africa accounts for over half of all child fatalities under the age of five. Noncommunicable diseases (NCDs) account for 37% of DALYs in Kenya, with neurological illnesses accounting for 70%. Alzheimer's and dementia fatalities in Kenya reached 1,827 in 2020, accounting for 0.69% of total deaths, according to the most recent WHO statistics. Kenya ranks 76 in the world with an age-adjusted death rate of 18.35 per 100,000 inhabitants.

Kenya's neurology clinical trial landscape is still in its early phases, with minimal clinical trial activity focusing on neurological illnesses. Historically, the bulk of clinical trials in Kenya has focused on infectious illnesses and non-communicable diseases such as cancer, cardiovascular disease, and diabetes. The low frequency of neurological illnesses in Kenya is one of the reasons for the country's minimal clinical trial activity in neurology.

The rising prevalence of neurological illnesses in Kenya, such as stroke, epilepsy, and Parkinson's disease, is spurring interest in clinical studies in this sector. Kenya's government and academic institutions are starting to invest in research infrastructure and training to support neurological clinical trial activities. Nairobi's Aga Khan University Hospital has begun a neurology research programme that includes clinical trials for neurological illnesses. Moreover, the Kenya Medical Research Institute (KEMRI) has begun to investigate options for conducting neurology clinical trials and has cooperated with global counterparts to establish clinical trial protocols.

Kenya Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

Many aspects influence neurology clinical trials in Kenya, including the country's high incidence of neurological illnesses such as epilepsy, stroke, and neuro infections. Moreover, the Kenyan government has invested in the healthcare system, including the establishment of specialist neurological care clinics, which may draw additional clinical trials to the nation. The favourable regulatory framework in Kenya, which includes the formation of regulatory agencies such as the Pharmacy and Poisons Board (PPB) and the National Commission for Science, Technology, and Innovation (NACOSTI), also contributes to the country's adoption of clinical trials.

Market Restraints

There are a number of obstacles to conducting clinical trials in Kenya. One of them is the country's inadequate research funding, which may impede the expansion of clinical trials. Moreover, a dearth of skilled people, such as neurologists and clinical trial coordinators, may impede the conduct of high-quality studies. Insufficient infrastructure, particularly clinical research and laboratory facilities, is another barrier. Moreover, there may be ethical considerations with clinical trial conduct in Kenya, such as informed consent and participant safety.

Competitive Landscape

Key Players

Merck & Co., Inc.
Novartis International AG
Roche Holding AG
Sanofi S.A.
GlaxoSmithKline plc
Johnson & Johnson
Biogen Inc.
Eli Lilly and Company
AstraZeneca plc

Notable Deals

March 2022, Roche planned to submit findings from its extensive and significant neuroscience portfolio at the 2022 AAN Annual Conference.

Healthcare Policies and Regulatory Landscape

The Pharmaceutical and Poisons Board (PPB) and the National Council for Science, Technology, and Innovation govern and monitor clinical research in Kenya (NACOSTI). Kenya's PPB is the regulatory body responsible for clinical trial approvals, supervision, and inspections, according to the Pharmacy and Poisons Act (PPA), the Pharmacy and Poisons (Conduct of Clinical Trials) Rules (CTRules), and the Guidelines for the Conduct of Clinical Trials in Kenya (G-KenyaCT. The PPB and its Expert Committee on Clinical Trials (ECCT) assess all clinical trial-related issues and provide approval for clinical trials to be undertaken in Kenya.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.